Berenberg Bank Remains Bullish on AstraZeneca PLC (AZN) – Here’s Why

Group 1 - AstraZeneca PLC (NASDAQ:AZN) is recognized as one of the best performing pharmaceutical stocks in 2025, with a Buy rating reiterated by Berenberg Bank and a price target of $95 [1] - The company announced positive full results from the Phase III TULIP-SC trial, showing that 56.2% of patients receiving Saphnelo (anifrolumab) experienced a reduction in disease activity at Week 52 compared to 37.1% in the placebo group [2] - The safety profile observed in the TULIP-SC trial was consistent with Saphnelo's known clinical profile, confirming the findings from the interim analysis as statistically significant [3] Group 2 - AstraZeneca PLC is a biopharmaceutical company engaged in the exploration, development, manufacturing, and commercialization of prescription medicines, supplying products to specialty and primary care physicians [4]